Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.01 par value
Symbol
VRDN on Nasdaq
Shares outstanding
82,051,282
Price per share
$31.12
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
93,206,726
Total reported value
$2,011,267,220
% of total 13F portfolios
0%
Share change
-1,402,001
Value change
-$24,960,102
Number of holders
167
Price from insider filings
$31.12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 15% $345,826,621 16,025,330 Fairmount Funds Management LLC 23 Oct 2025
Venrock Healthcare Capital Partners III, L.P. 4.5% $42,152,893 3,575,309 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
Commodore Capital LP 3.9% -28% $69,056,000 -$23,738,000 3,200,000 -26% Commodore Capital LP 30 Sep 2025

As of 30 Sep 2025, 167 institutional investors reported holding 93,206,726 shares of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN). This represents 114% of the company’s total 82,051,282 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) together control 89% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 12,249,355 +0.09% 0.01% $264,341,081
BlackRock, Inc. 6.6% 5,428,521 -1.7% 0% $117,147,485
Deep Track Capital, LP 6.6% 5,380,449 0% 3.2% $116,110,089
Kynam Capital Management, LP 5.4% 4,427,927 0% 7.1% $95,554,665
VANGUARD GROUP INC 5.3% 4,331,983 -3.9% 0% $93,484,193
VR ADVISER, LLC 4.7% 3,882,709 0% 4.7% $83,788,860
Fairmount Funds Management LLC 4.2% 3,459,913 0% 6.7% $74,664,923
Commodore Capital LP 3.9% 3,200,000 -34% 3.4% $69,056,000
TANG CAPITAL MANAGEMENT LLC 3.5% 2,842,925 0% 2.4% $61,350,322
Paradigm Biocapital Advisors LP 3.2% 2,609,353 -4.8% 1.7% $56,309,838
STATE STREET CORP 3.1% 2,554,166 +0.03% 0% $55,118,902
PRICE T ROWE ASSOCIATES INC /MD/ 2.9% 2,418,104 -16% 0.01% $52,184,000
NOVO HOLDINGS A/S 2.9% 2,380,000 0% 3.3% $51,360,400
MAVERICK CAPITAL LTD 2.7% 2,212,701 -2% 0.64% $47,750,088
Eversept Partners, LP 2.3% 1,924,306 +1.1% 3.2% $41,526,523
ALLIANCEBERNSTEIN L.P. 2.3% 1,859,458 -4.3% 0.01% $40,127,104
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,766,187 +1.5% 0% $38,120,267
BAKER BROS. ADVISORS LP 2.1% 1,744,406 0% 0.27% $37,644,281
LOOMIS SAYLES & CO L P 1.9% 1,550,328 +16% 0.04% $33,456,078
PERCEPTIVE ADVISORS LLC 1.8% 1,462,400 +227% 0.92% $31,558,592
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.5% 1,220,128 +10% 0.04% $26,330,362
Fisher Asset Management, LLC 1.5% 1,201,226 +136% 0.01% $25,922,455
Parkman Healthcare Partners LLC 1.4% 1,154,487 -11% 2.7% $24,913,829
WELLINGTON MANAGEMENT GROUP LLP 1.4% 1,122,532 +315% 0% $24,224,240
Pictet Asset Management Holding SA 1.3% 1,049,385 -17% 0.02% $22,645,728

Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 213,482 $6,643,861 -$1,335,686 $31.12 5
2025 Q3 93,206,726 $2,011,267,220 -$24,960,102 $21.58 167
2025 Q2 94,556,649 $1,321,909,936 +$44,977,637 $13.98 169
2025 Q1 91,362,527 $1,231,596,559 -$2,448,888 $13.48 174
2024 Q4 91,041,740 $1,745,285,977 +$57,671,095 $19.17 177
2024 Q3 86,940,196 $1,978,662,987 +$415,131,771 $22.75 165
2024 Q2 69,502,343 $904,301,498 -$23,098,956 $13.01 137
2024 Q1 70,991,123 $1,242,949,209 +$175,692,448 $17.51 135
2023 Q4 23,275 $506,930 -$810,235 $21.78 2
2023 Q3 50,192,424 $769,944,641 +$30,455,882 $15.34 122
2023 Q2 47,119,787 $1,121,040,896 +$92,578,112 $23.79 127
2023 Q1 43,068,809 $1,095,674,563 +$40,970,202 $25.44 134
2022 Q4 40,909,654 $1,194,969,493 +$88,213,786 $29.21 119
2022 Q3 37,776,709 $774,600,096 +$210,255,842 $20.51 101
2022 Q2 28,247,430 $326,826,712 +$27,411,391 $11.57 76
2022 Q1 24,929,839 $460,937,688 +$26,453,346 $18.49 71
2021 Q4 23,259,955 $459,848,025 +$113,446,724 $19.77 52
2021 Q3 13,600,156 $223,718,000 +$122,961,895 $16.45 38
2021 Q2 6,003,456 $109,804,000 +$18,372,890 $18.29 24
2021 Q1 5,090,631 $84,547,000 +$80,720,029 $16.71 29
2020 Q4 229,000 $3,767,000 +$3,767,002 $16.46 2